Real Life Experience of the Use of CDK 4/6 Inhibitors in the First Line Treatment of Metastatic ER+ Her2 – Breast Cancer: Focus in Neutropenia and Dose Reduction

Purpose: To assess the benefit of routine blood counts within the first 2 cycles of initiation of CDK 4/6 inhibitor therapy and following 6 cycles of therapy.

Source: Clinical Oncology - July 8, 2020 Category: Radiology Authors: C. Blake, S. Cleator, A. Brown Source Type: research